HypotrichosisNCT07775989
Evaluation of the Efficacy and Safety of Dallixa® Eyebrow Serum (Produced by Quantum Aesthetics Cosmetics, Turkey) in Subjects With Eyebrow Hypotrichosis
A study testing dermo cosmetic product in people with Hypotrichosis, run by Quantum Aesthetics Cosmetics at 1 site in Turkey (Türkiye).
Trial summary
A retrospective, single arm, and interventional Clinical Trial Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypotrichosis
- What is being tested?
- dermo cosmetic product
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 49 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 28 Aug 2025to 20 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Individuals of any sex and at least 18 years of age
- Subjects who have inadequate eyebrow due to natural causes (eyebrow hypotrichosis)
- A Grade 1 or 2 on the Global Eyebrow Assessment (GEBA) scale
- Subjects who agree to forgo any additional treatment to the brows, such as waxing, plucking, threading and/or tinting, laser hair removal, and/or bleaching for the duration of the study.
- Willing to complete all required study visits, procedures, and evaluations including photography.
Who cannot join
- Subjects with any uncontrolled systemic disease (like systemic diseases which could prevent hair growth or produce abnormal growth)
- known diagnoses possibly underlying or contributing to the state of the eyebrows including, but not limited to, telogen effluvium or anagen effluvium
- Any known diseases, infection or abnormalities to the eyelid or eyebrow (including eczema, seborrheic dermatitis, alopecia areata, trichotillomania, thyroid diseases, atopic dermatitis, history of trauma or burn to the eyebrow region and etc.)
- Subjects that have thinning brows as a result of over plucking, trichotillomania, chemotherapy or any other condition or treatment that causes hair loss.
- Patients with permanent eyebrow loss due to over-grooming
- Allergy to any component of the investigational product
Show all 20Show fewer
- Subjects with temporary or semipermanent eyebrow fillers, any permanent or semi-permanent tint, dye or bleaching within 3 months
- Any skin pigmentation/depigmentation, microblading, tattoos, permanent eye and/or eyebrow make-up, moles, scars, or other characteristics within the eyebrow area
- Subjects who used permanent injectable fillers in and around the eyebrow area within 12 months
- Use of any over-the-counter or prescription eyebrow growth product within 3 months
- Subjects who had undergone any facial surgery (e.g., brow lift) or eyebrow extension within 3 months of screening
- Current enrollment in an investigational product or device or participation in such a study within 30 days
- Aphakic subjects and/or pseudophakic subjects with a torn posterior lens capsule
- Subjects with known risk factors for macular edema
- Patients with a history of glaucoma and/or increased ocular pressure
- Patients who are currently using an IOP-lowering prostaglandin analog
- Previous cosmetic surgery to the upper face (e.g., periorbital surgery, brow lift, eyelid or eyebrow surgery, etc.).
- Any planned facial cosmetic procedure that would interfere with the evaluation of the eyebrows
- Participation in another investigational product or device study within the last 30 days
- Females who are pregnant, nursing, or planning a pregnancy during the study, or who are of childbearing potential and not using a reliable method of contraception
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy and Safety of Dallixa® Eyebrow Serum in Eyebrow Hypotrichosis
A retrospective, single arm, and interventional Clinical Trial
- Conditions
- Hypotrichosis
- Being tested
- dermo cosmetic product
- Medical subject headings
- Hypotrichosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
dermo cosmetic productOther
dermo cosmetic product like herbal or vitamin ingredients
| Study group | Role | What they receive |
|---|---|---|
| Dallixa® Eyebrow Serum | Experimental | Not described Receives: Other: dermo cosmetic product |
What is being measured
The primary outcome is the main question the study is designed to answer.
The proportion of subjects with ≥ 1-grade increase in GEBA Score at month 5
Measured: at 5 month
Secondary outcomes (5)
The proportion of subjects with ≥ 1-grade increase in the GEBA at month 2
Measured: at month2
Change from baseline in eyebrow diameter at month 2 and 5 (Based on DIA)
Measured: at month 2 and 5
Change from baseline in eyebrow density at month 2 and 5 (Based on DIA)
Measured: at month 2 and 5
The proportion of satisfied subjects (very satisfied/mostly satisfied) on Eyebrow Satisfaction Scale (ESS) Item 6 at month 2 and 5
Measured: at month 2 and 5
Adverse events reported from the baseline and during the study period (from the baseline up to week 20)
Measured: from the baseline up to week 20
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2026
- Study start28 Aug 2025
- Primary completion20 Apr 2026
- Study completion20 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypotrichosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 49 participants (actual)
Sponsor and investigators
- Lead sponsor
- Quantum Aesthetics Cosmetics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07775989
- Sponsor's protocol ID
- DallKas.Qua.AA.IV.2025
- Status last verified
- Nov 2026
- First submitted
- 17 Aug 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: no planing to share individual participant data yet
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Dallixa® Eyebrow Serum in Eyebrow Hypotrichosis
- ClinicalTrials.gov ID
- NCT07775989
- Acronym / sponsor ID
- DallKas.Qua.AA.IV.2025
- Conditions
- Hypotrichosis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 49 participants (actual)
- Lead sponsor
- Quantum Aesthetics CosmeticsIndustry (pharma, biotech, devices)
- Study start
- 28 Aug 2025 (actual)
- Primary completion
- 20 Apr 2026 (actual)
- Study completion
- 20 Apr 2026 (actual)
- First posted
- 20 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A retrospective, single arm, and interventional Clinical Trial
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Dallixa® Eyebrow Serum | Experimental | Other: dermo cosmetic product |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Individuals of any sex and at least 18 years of age
- Subjects who have inadequate eyebrow due to natural causes (eyebrow hypotrichosis)
- A Grade 1 or 2 on the Global Eyebrow Assessment (GEBA) scale
- Subjects who agree to forgo any additional treatment to the brows, such as waxing, plucking, threading and/or tinting, laser hair removal, and/or bleaching for the duration of the study.
- Willing to complete all required study visits, procedures, and evaluations including photography.
Key exclusion criteria (20 listed)
- Subjects with any uncontrolled systemic disease (like systemic diseases which could prevent hair growth or produce abnormal growth)
- known diagnoses possibly underlying or contributing to the state of the eyebrows including, but not limited to, telogen effluvium or anagen effluvium
- Any known diseases, infection or abnormalities to the eyelid or eyebrow (including eczema, seborrheic dermatitis, alopecia areata, trichotillomania, thyroid diseases, atopic dermatitis, history of trauma or burn to the eyebrow region and etc.)
- Subjects that have thinning brows as a result of over plucking, trichotillomania, chemotherapy or any other condition or treatment that causes hair loss.
- Patients with permanent eyebrow loss due to over-grooming
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| dermo cosmetic productdermo cosmetic product like herbal or vitamin ingredients | Other | Dallixa® Eyebrow Serum |
Primary outcome
The proportion of subjects with ≥ 1-grade increase in GEBA Score at month 5
Time frame: at 5 month
5 secondary outcomes
The proportion of subjects with ≥ 1-grade increase in the GEBA at month 2
Time frame: at month2
Change from baseline in eyebrow diameter at month 2 and 5 (Based on DIA)
Time frame: at month 2 and 5
Change from baseline in eyebrow density at month 2 and 5 (Based on DIA)
Time frame: at month 2 and 5
The proportion of satisfied subjects (very satisfied/mostly satisfied) on Eyebrow Satisfaction Scale (ESS) Item 6 at month 2 and 5
Time frame: at month 2 and 5
Adverse events reported from the baseline and during the study period (from the baseline up to week 20)
Time frame: from the baseline up to week 20
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No. no planing to share individual participant data yet
Related trials for Hypotrichosis
Active, not recruitingPhase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
RecruitingPhase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Active, not recruitingObservational study
Litfulo Capsules Special Investigation
Alopecia Areata
Active, not recruitingObservational study
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Alopecia Areata
Active, not recruitingObservational study
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing dermo cosmetic product in people with Hypotrichosis, run by Quantum Aesthetics Cosmetics at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The proportion of subjects with ≥ 1-grade increase in GEBA Score at month 5 (time frame: at 5 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.